Apellis Pharmaceuticals Inc(APLS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 41.01 | EPS (ttm) | 1 | Insider Own | 30.77% | Shs Outstand | 127.9M | Perf Week | - |
| Market Cap | 5.25B | Forward P/E | - | EPS next Y | 74.86% | Insider Trans | -0.31% | Shs Float | 88.6M | Perf Month | 0.1% |
| Enterprise Value | 5.32B | PEG | - | EPS next Q | -0.24 | Inst Own | 110.31% | Short Float | 12.13% | Perf Quarter | 89.6% |
| Income | 0.13B | P/S | 4.75 | EPS this Y | -665% | Inst Trans | -9.08% | Short Ratio | 1.68 | Perf Half Y | 103.83% |
| Sales | 1.11B | P/B | 12.65 | EPS next 5Y | 53.35% | ROA | 14.1% | Short Interest | 10.75M | Perf YTD | 63.34% |
| Book/sh | 3.24 | P/C | 12.91 | EPS past 3/5Y | - | ROE | 46.02% | 52W High | -0.27% ($41.14) | Perf Year | 137.44% |
| Cash/sh | 3.18 | P/FCF | 140.18 | Sales past 3/5Y | 136.98% 31.98% | ROIC | 16.87% | 52W Low | 154.84% ($16.10) | Perf 3Y | -53.35% |
| Dividend Est. | - | EV/EBITDA | 31.94 | EPS Y/Y TTM | 158.69% | Gross Margin | 90.09% | Volatility(W/M) | 0.13% 0.15% | Perf 5Y | -10.1% |
| Dividend TTM | - | EV/Sales | 4.81 | Sales Y/Y TTM | 42.46% | Oper. Margin | 14.95% | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.16 | EPS Q/Q | 119.32% | Profit Margin | 12.06% | RSI (14) | 84.48 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.63 | Sales Q/Q | 60.85% | SMA20 | 0.14% ($40.97) | Beta | -0.25 | Target Price | $41 |
| Payout | - | Debt/Eq | 1.15 | Earnings | 2026/2/24 | SMA50 | 26.8% ($32.36) | Rel Volume | 0 | Prev Close | $41.03 |
| Employees | 739 | LT Debt/Eq | 0.9 | EPS/Sales Surpr. | -25.67% 0.26% | SMA200 | 58.68% ($25.86) | Avg Volume(3M) | 6.42M | Price | $41.03 |
| IPO | 2017/11/9 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
Company
APLS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A commercial-stage biotech company that develops and markets therapeutics targeting the complement pathway of the immune system. It sells an ophthalmic injection for age-related retinal diseases and treatments for rare blood and kidney disorders. As a healthcare stock, its value is driven by core therapeutic revenue, label expansions, and the competitive landscape.
Over the past 1 year, on the higher side
0% below its 1-year high.
APLS makes money exceptionally well
14.95% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -665.0% this year.
Tap to view numbers
But it is not cheap
Trading at 41.0 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -53.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 110.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBP 0.03%
XBI 0.02%
MNA 0.02%
SBIO 0.02%
LABU 0.02%It ranks #4 in the industry
Based on market cap of $5B.
APLS $5B PER 41.0
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is APLS?
APLS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APLS?
The market cap of APLS is approximately $5.3B, ranking 1,352 within its sector.
What is the P/E ratio of APLS?
APLS has a P/E ratio of approximately 41.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for APLS?
APLS has recorded a 52-week high of $41.14 and a low of $16.10.
